FDA approval, fundraising, and the reality of building in healthcare according to BioticsAI founder

2026-04-30 · Source: TechCrunch · Field: Business & Management — Entrepreneurship & Start-ups, Corporate Strategy & Leadership, Operations & Process Management · Depth: Intermediate, extended

Summary

BioticsAI, co-founded by Robhy Bustami, is developing an AI copilot for ultrasound to detect fetal abnormalities, operating within the highly regulated healthcare sector. The company achieved FDA approval in January 2026, a significant milestone following their 2023 TechCrunch Startup Battlefield win. BioticsAI's approach involved integrating clinical validation and regulatory strategy from the outset, engaging early with regulators through pre-submission meetings, and conducting structured clinical studies. This strategy contrasts with the "build fast and break things" mentality often seen in tech. Bustami emphasizes the importance of a strong company culture, particularly for maintaining team motivation during long regulatory timelines, and the need for transparency and support during challenging periods like workforce reductions. The company is now entering its deployment phase, rolling out its technology in hospitals and planning expansion into broader reproductive health.

Key takeaway

For founders building in regulated industries like healthcare, your focus must shift from rapid iteration to meticulous, integrated regulatory planning. Prioritize early engagement with regulatory bodies and cultivate a transparent, supportive company culture to sustain motivation through extended timelines. This approach, exemplified by BioticsAI's FDA approval, mitigates risk and builds a foundation for long-term success, even if it means a slower initial pace.

Key insights

Navigating highly regulated sectors like healthcare demands rigor, early regulatory engagement, and a resilient company culture.

Principles

• Integrate regulatory strategy from day one.
• Culture is defined by daily decisions, not written statements.
• Prioritize learning from mistakes over assigning blame.

Method

BioticsAI integrated clinical validation, regulatory strategy, and product development into a single process, including early regulator engagement and structured clinical studies, to secure FDA approval for its AI ultrasound copilot.

In practice

• Engage regulators early via pre-submission meetings.
• Foster a culture of alignment across diverse teams.
• Prioritize essential tasks to avoid burnout.

Topics

• FDA Approval Process
• AI in Healthcare
• Startup Scaling
• Layoff Management
• Confidential Computing

Best for: Entrepreneur, Investor, Director of AI/ML

Related on AIssential

• I Sold My Startup A Year After Founding It. Here’s Why That Was The Fastest Way To Build Real-World Healthcare AI — Clinical AI success requires deep integration within existing healthcare systems to achieve real-world reliability and impact.
• A Sputnik moment: China's beating the US in neuroscience — China's rapid neurotechnology advancements, driven by national priority and faster regulation, challenge US scientific preeminence.
• Yseop Featured in mind Health: Accelerating Drug Approvals with Regulatory-Grade AI — AI is transforming regulatory writing, accelerating new therapy access.
• Humanising Healthcare - AI and Innovation at Optum — Human-centered innovation and responsible AI are crucial for transforming healthcare and improving patient outcomes.
• Decentralized Trials That Scale Globally Without Compliance Risks - with Emma Vitalini of Amgen — AI and decentralized trials accelerate patient recruitment and enhance compliance in regulated healthcare.
• Expanding our AI and Healthcare Portfolio — AI deployment in healthcare, driven by profit, poses significant risks to patient safety, worker dignity, and democratic oversight.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by TechCrunch.